Ken Griffin Arvinas, Inc. Call Options Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2025
Call Options
11 transactions
Others Institutions Holding ARVN
# of Institutions
246Shares Held
65.9MCall Options Held
2.77MPut Options Held
1.1M-
Vanguard Group Inc Valley Forge, PA9.39MShares$63.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.26MShares$42.5 Million0.0% of portfolio
-
Logos Global Management LP San Francisco, CA3.3MShares$22.4 Million3.14% of portfolio
-
Opaleye Management Inc. Boston, MA1.98MShares$13.4 Million3.81% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL1.8MShares$12.2 Million0.05% of portfolio
About ARVINAS, INC.
- Ticker ARVN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,205,300
- Market Cap $361M
- Description
- Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...